Cytarabine-13C3
(Synonyms: Ara-C-13C3, 1-β-D-Arabinofuranosylcytosine-13C3) 目录号 : GC45800A neuropeptide with diverse biological activities
Sample solution is provided at 25 µL, 10mM.
Cytarabine-13C3 is intended for use as an internal standard for the quantification of cytarabine by GC- or LC-MS. Cytarabine is a nucleoside analog that differs from cytosine by the presence of a hydroxyl group at the 2' position of the sugar residue. It is triphosphorylated in vivo to produce ara-C, a competitive inhibitor of DNA polymerases α and β (Kis = 4 and 32 μM, respectively).1,2,3 At low concentrations, ara-C is incorporated into DNA, slowing but not stopping DNA synthesis.4 It has antiviral activity against certain types of viruses.5 Formulations containing cytarabine have been used in the treatment of leukemia.4
|1. Furth, J.J., and Cohen, S.S. Inhibition of mammalian DNA polymerase by the 5'-triphosphate of 1-β-D-arabinofuranosylcytosine and the 5'-triphosphate of 9-β-D-arabinofuranoxyladenine. Cancer Res. 28(10), 2061-2067 (1968).|2. Graham, F.L., and Whitmore, G.F. Studies in mouse L-cells on the incorporation of 1-β-D-arabinofuranosylcytosine into DNA and on inhibition of DNA polymerase by 1-β-D-arabinofuranosylcytosine 5'-triphosphate. Cancer Res. 30(11), 2636-2644 (1970).|3. Yoshida, S., Yamada, M., and Masaki, S. Inhibition of DNA polymerase-α and -β of calf thymus by 1-β-D-arabinofuranosylcytosine-5'-triphosphate. Biochim. Biophys. Acta. 477(2), 144-150 (1977).|4. Pourquier, P., Takebayashi, Y., Urasaki, Y., et al. Induction of topoisomerase I cleavage complexes by 1-β-D-arabinofuranosylcytosine (ara-C) in vitro and in ara-C-treated cells. Proc. Nat. Acad. Sci. USA 97(4), 1885-1890 (2000).|5. Volmer, R., Bajramovic, J.J., Schneider, U., et al. Mechanism of the antiviral action of 1-β-D-arabinofuranosylcytosine on Borna disease virus. J. Virol. 79(7), 4514-4518 (2005).
Cas No. | N/A | SDF | |
别名 | Ara-C-13C3, 1-β-D-Arabinofuranosylcytosine-13C3 | ||
Canonical SMILES | O[C@@H]1[C@H](N2C(N=[13C](N)[13CH]=[13CH]2)=O)O[C@H](CO)[C@H]1O | ||
分子式 | C6[13C3]H13N3O5 | 分子量 | 246.2 |
溶解度 | DMSO: warmed,Water: slightly soluble | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 4.0617 mL | 20.3087 mL | 40.6174 mL |
5 mM | 0.8123 mL | 4.0617 mL | 8.1235 mL |
10 mM | 0.4062 mL | 2.0309 mL | 4.0617 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet